Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients

  • STATUS
    Recruiting
  • participants needed
    40
  • sponsor
    Hasselt University
Updated on 19 February 2024
cancer
chronic obstructive pulmonary disease
COPD
covid-19

Summary

The primary objective of the study is to evaluate cardiac and pulmonary hemodynamic changes over time as predictor of disease progression and outcome in COVID-19 patients admitted to ICU.

The primary endpoint is the occurrence of a major event predefined as either: death (all-cause mortality) or discharge from ICU (limit of 4 months).

This is a uni-center prospective observational cohort study with an inclusion period of 2 months. The end of the study is foreseen in 6 months.

Description

Background COVID-19 can lead to a bilateral pneumonia overwhelming the lungs causing dyspnea and respiratory distress. Up to 20% of the infected population is hospitalized and 5% is submitted to the intensive care unit (ICU). Up to 31% of patients in ICU develop sepsis and 61% develop ARDS with a deadly outcome at ICU of 38%. While sepsis typically causes diffuse vasodilation, the pulmonary vasculature resistance in ARDS is high. Although heart failure is per definition not the cause of ARDS, the resulting elevated pressures in the pulmonary circulation affect right and left heart function. Early detection in alterations of cardiac and pulmonary hemodynamics might prompt to actions to prevent ARDS.

Primary objective To evaluate cardiac and pulmonary hemodynamic changes over time as predictor of disease progression and outcome in COVID-19 patients admitted to ICU.

Secondary objective

  • Analysis of prognostic factors based on the data at initial presentation
  • Performing a trajectory analysis of the time course during ICU stay to determine what leads to optimal outcome - gain insight in the pathophysiology of the cardio-pulmonary evolution of COVID-19 pts
  • Feasibility study for the creation of an individualized expected data-trajectory for new cases and continuously updating its visualization in relation to the expected trajectory related to an improved outcome
  • Evaluate how Machine Learning, based on manifold learning for quantifying information similarity and its temporal evolution, is able to predict outcome using rich data in a limited number of patients Primary Endpoint

Occurrence of a major event predefined as either:

  • Death (all-cause mortality)
  • Discharge from ICU (limit of 4 months) Secondary Endpoint
  • Decrease of left ventricular (LV) function defined by LV global longitudinal strain (GLS) > 5% (absolute value) and LV S' as compared to the initial evaluation
  • Evolution of LV diastolic function related to prognosis - Doppler Data and ML interpretation
  • Decrease of right ventricular (RV) function by RV GLS > 5% (absolute values) or decrease of RV S' to an absolute value <9.5 cm/s
  • Dynamic RV response to PEEP maneuver to differentiate intrinsic RV dysfunction from excessive PEEP.
  • Changes in pulmonary arterial compliance from RVOT-VTI and PASP Methods Uni-center cohort study (Prospective Observational) Duration of the study Duration of the inclusion period: 2 months Duration of participation for each patient: average 4 weeks until death or discharge from ICU Duration of data processing and reports: 4 months Total duration of the study: 6 months

Details
Condition Covid 19
Age 100 years and younger
Treatment No interventions planned
Clinical Study IdentifierNCT04371679
SponsorHasselt University
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient admitted to ICU that is COVID-19 positive based on rt-PCR
Ventilated or not ventilated
No restrictions on age
No restrictions on comorbidities or a diversity of underlying pathology (malignancies, COPD, )

Exclusion Criteria

Patients that are not COVID-19 tested (rt-PCR) or where the diagnosis is pending
Patients that refuse their participation in the study
Patients under legal protection, or deprived of their liberty
Patients that are so critically ill that a minimum of 1 follow-up is very unlikely to be realised
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.